Cassie K. Chou, MD, PhD

Cassie K. Chou, MD, PhD
  • Other Publications

    • Gauthier J, Bezerra ED, Hirayama AV, Fiorenza S, Sheih A, Chou CK, Kimble EL, Pender BS, Hawkins RM, Vakil A, Phi TD, Steinmetz RN, Jamieson AW, Bar M, Cassaday R, Chapuis A, Cowan AJ, Green DJ, Kiem HP, Milano F, Shadman M, Till B, Riddell SR, Maloney DG, Turtle CJ
      Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies.
      32967009 Blood, 2020 Sept. 23
    • Chou CK, Turtle CJ
      Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
      32067497 Expert opinion on biological therapy, 2020 June : 20(6)653-664 PMCID:PMC7393694
    • Chou CK, Turtle CJ
      Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy.
      31431714 Bone marrow transplantation, 2019 Aug. : 54(Suppl 2)780-784
    • Chou CK, Schietinger A, Liggitt HD, Tan X, Funk S, Freeman GJ, Ratliff TL, Greenberg NM, Greenberg PD
      Cell-intrinsic abrogation of TGF-beta signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer.
      22984076 Journal of immunology (Baltimore, Md. : 1950), 2012 Oct. 15 : 189(8)3936-46 PMCID:PMC3466379
    • Dunn W, Chou C, Li H, Hai R, Patterson D, Stolc V, Zhu H, Liu F
      Functional profiling of a human cytomegalovirus genome.
      14623981 Proceedings of the National Academy of Sciences of the United States of America, 2003 Nov. 25 : 100(24)14223-8 PMCID:PMC283573


Medical/Professional School

University of Washington School of Medicine, Seattle


University of Washington, Seattle


University of Washington School of Medicine, Seattle

Research Focus Area

Immunotherapy, CAR-T cells